Aardvark Therapeutics (AARD) vs Soleno (SLNO) – ARD-101 vs Vykat XR, Prader-Willi PWS Battle and Phase 3 HERO 2026 Catalyst

Executive Summary

Aardvark Therapeutics (AARD) is one of the more interesting new names in the rare-disease/obesity intersection: a clinical-stage biotech built around a gut-restricted small-molecule (ARD-101) targeting bitter taste receptors (TAS2Rs) to modulate hunger signaling. The core story is very focused: Prader–Willi syndrome (PWS), an ultra-rare genetic disease dominated by uncontrolled hyperphagia and weight gain, with ARD-101 in a pivotal Phase 3 trial (HERO) that has aligned with the FDA and, after the October 2025 expansion, is now guided to deliver topline results in Q3 2026.

The key comparison is Soleno Therapeutics (SLNO), whose Vykat XR (diazoxide choline extended-release) became in March 2025 the first FDA-approved therapy for hyperphagia in PWS. Soleno is now a commercial-stage company with a much larger market cap and a sizable cash balance backing its launch. Aardvark sits earlier in the curve: lower market cap, strong specialist investor base, no revenue yet, but a shot at becoming the first true competitor in this niche if Phase 3 confirms what Phase 2 already hinted: meaningful reductions in hyperphagia scores with a clean safety profile and a mechanism that may be easier to combine with GLP-1s and other metabolic agents.

Phase 2 data for ARD-101 in PWS showed an average reduction of about seven points on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) in treated patients, with very favorable tolerability and largely gut-restricted exposure. The pivotal HERO Phase 3, initiated in December 2024, has been designed in explicit dialogue with the FDA and, based on the most recent guidance, is expected to deliver topline results in Q3 2026. On the other side of the table, Vykat XR demonstrated robust HQ-CT reductions in its pivotal program but carries known on-target adverse events such as hyperglycemia and fluid retention typical of diazoxide-based therapy.

At today’s prices, we are looking at a classic asymmetric setup: Aardvark’s valuation sits in the lower hundreds of millions of dollars, versus Soleno’s multi-billion market cap anchored by the first-to-market launch. If ARD-101 clears Phase 3 with solid efficacy and a cleaner tolerability profile, especially in less severe PWS and in combination with other metabolic drugs, the path to a meaningful share of a high-value, albeit small, market is credible. The flip side is pure binary risk on the Phase 3 dataset and the usual financing risk that comes with being pre-revenue. Nothing here is a recommendation to buy or sell; this is a descriptive analysis of the setup, risks and possible scenarios.

Company Overview – Aardvark Therapeutics

Aardvark Therapeutics is a clinical-stage biopharmaceutical company headquartered in the San Diego/La Jolla biotech cluster and founded in 2017 by Dr. Tien-Li Lee, who still serves as CEO and Chairman of the Board. The company’s mission is tightly focused: develop novel small-molecule therapeutics that activate innate homeostatic pathways to treat hunger-driven metabolic diseases. In practice, that means targeting bitter taste receptors (TAS2Rs) in the gut to trigger the release of satiety hormones such as cholecystokinin (CCK) and GLP-1, while limiting systemic exposure to avoid off-tissue toxicity.

Aardvark’s lead asset, ARD-101 (denatonium acetate monohydrate), is an oral, gut-restricted TAS2R agonist. It has completed Phase 1 in healthy volunteers and a Phase 2 trial in PWS, and is now in a pivotal Phase 3 (HERO) trial in PWS hyperphagia after alignment with the FDA on trial design and endpoints. Beyond PWS, Aardvark plans to evaluate ARD-101 in hypothalamic obesity (HO) and to develop ARD-201, a fixed-dose combination of ARD-101 with a DPP-4 inhibitor, for broader obesity and weight maintenance indications.

The investor base is classic for a serious late-private/IPO rare-disease story: Decheng Capital, Cormorant Asset Management, Vickers Venture Partners, Surveyor Capital, SymBiosis and the Foundation for Prader–Willi Research are all cited in company and local media coverage as key backers, and Dr. Lee himself is reportedly the largest individual shareholder with close to 20% of the company according to the S-1 and post-IPO coverage.

CEO and management profile

Dr. Tien-Li Lee brings over 20 years of biotech experience, spanning immunology, oncology, cardiovascular, neurology and infectious disease. Before founding Aardvark in 2017, he served as Chief Strategy Officer at NantKwest (now part of ImmunityBio), and he is listed as inventor or co-inventor on multiple biomedical innovations licensed to several companies. He trained in medicine at UC San Diego and completed post-graduate training in Internal Medicine and Physical Medicine & Rehabilitation in the UC system. The S-1 describes a management team with broad experience at companies like Amylin, Roche, Johnson & Johnson and ViaCyte, with a CMO who previously helped steer a cell-therapy company to a $320M acquisition and a COO with extensive late-stage development experience.

From a RunUP-style perspective, that matters: a Phase 3 trial in a rare disease is not just about a molecule and a p-value; it’s about execution, trial operations, site selection, and the ability to handle inevitable surprises without losing timelines. Aardvark’s team profile is more “under the radar specialist” than “tourist management team dropped in from Big Pharma”, which lines up well with the PWS focus.

Disease and Market Context – Prader–Willi Syndrome (PWS)

PWS is a rare genetic neurodevelopmental disorder caused by the loss of function of specific paternal genes on chromosome 15. Clinically, the picture evolves through phases: early hypotonia and feeding difficulties, followed by rapid weight gain and then a chronic phase dominated by hyperphagia, compulsive food-seeking and behavioral issues. Hyperphagia is not a “big appetite” problem; for many families it is a 24/7 management crisis requiring locked fridges, restricted environments and constant supervision.

Epidemiological estimates vary, but most sources converge on a prevalence of roughly 1 in 15,000–30,000 births, with around 10,000–20,000 diagnosed patients in the U.S. and perhaps 30,000–50,000 worldwide. The economic burden is substantial: repeated hospitalizations, specialized care homes, caregiver burnout, and severe comorbidities such as type 2 diabetes, sleep apnea and cardiovascular problems. Even in orphan-disease terms, PWS is exactly the kind of indication where payers and health systems are willing to pay for therapies that reduce crisis events and allow safer, more independent living.

Before Vykat XR, there were no FDA-approved therapies specifically targeting hyperphagia in PWS; management relied on strict environmental control, off-label medications (e.g., antipsychotics, stimulants, SSRIs) and general obesity strategies. That made Soleno’s approval an important milestone not just clinically but also in terms of market “proof of concept”: payers now have a labeled product and an established framework for reimbursing PWS hyperphagia treatment.

Market research for PWS hyperphagia therapies suggests a global addressable market in the hundreds of millions of dollars annually, with upside towards the $0.6–1.0B range if diagnosis improves, if real-world data confirm strong quality-of-life benefits and if multiple therapies are used sequentially or in combination. In that context, a second drug with differentiated biology and safety isn’t a marginal add-on; it could structurally expand the treated population and help anchor the category.

Pipeline and Clinical Data – ARD-101 vs Vykat XR

ARD-101 (Aardvark) – Mechanism and Phase 2 signal

ARD-101 is a first-in-class, oral, gut-restricted agonist of selected bitter taste receptors (TAS2Rs) in the gut lumen. The hypothesis, articulated in the S-1 and multiple company communications, is that stimulating these receptors on enteroendocrine cells triggers local release of CCK and GLP-1, activating the gut–brain axis and sending satiety signals without the systemic exposure and pancreatitis risk that have historically plagued direct CCK receptor agonists.

In the completed Phase 2 trial in PWS hyperphagia, ARD-101 showed both encouraging efficacy signals and an attractive safety/tolerability profile:

– In the first part of the study, 12 subjects completed 28 days of ARD-101 200 mg BID followed by a 14-day withdrawal period. Among the eight subjects with evaluable HQ-CT scores, the average reduction in HQ-CT score was approximately seven points, with no treatment-related adverse events reported.
– In a second part with an up-titration regimen (400→600→800 mg BID), four subjects completed the protocol and again showed a roughly seven-point reduction in HQ-CT with only Grade 1 treatment-related events.

Systemic exposure was low, consistent with a gut-restricted mechanism. That’s important when you think about extension into broader obesity and combination use with GLP-1 receptor agonists: ARD-101 is designed to complement appetite-suppressing GLP-1s by acting more on hunger and satiety, potentially stabilising weight after GLP-1 withdrawal or improving tolerability at lower GLP-1 doses.

HERO Phase 3 – Pivotal trial design

The HERO trial (Hunger Elimination or Reduction Objective) is Aardvark’s pivotal Phase 3 study in PWS hyperphagia. According to the S-1 and company updates, the trial:

– Was initiated in December 2024 after alignment with the FDA on design and endpoints.
– Targets PWS patients with significant hyperphagia, including adolescents and adults, with global recruitment across multiple regions (North America, Europe, selected Asia-Pacific countries).
– Uses change in HQ-CT as the primary endpoint over a 12-week blinded treatment period, with secondary endpoints likely including caregiver-reported outcomes, behavioral measures and weight-related metrics.
– Is explicitly described as “potentially pivotal” and intended to support an NDA if successful, with topline data now anticipated in Q3 2026 after the trial expansion communicated in October 2025.

From a RunUP perspective, this is a textbook binary catalyst: a single, concentrated readout with high-information content. The set-up also has an important nuance: because Vykat XR is already on the market, regulators, families and physicians now have a benchmark for what “meaningful” hyperphagia improvement looks like. Aardvark needs not only a statistically positive HQ-CT delta but a profile that makes sense in the real world against that benchmark.

ARD-201 and broader metabolic pipeline

Beyond PWS, Aardvark is advancing ARD-201, a fixed-dose combination of ARD-101 and a DPP-4 inhibitor for obesity and obesity-related conditions. Preclinical studies described in the S-1 show additive effects on weight loss when ARD-101 is combined with DPP-4 inhibition or GLP-1 receptor agonists, which fits the broader industry theme of combination regimens to deepen or maintain weight loss without intolerable side effects.

The EMPOWER Phase 2 trial is planned as a multi-arm study exploring various combinations of ARD-101, GLP-1s and other agents, with a particular eye on weight regain after GLP-1 withdrawal and on GI tolerability. These programs are upside levers rather than near-term valuation anchors, but if HERO hits and PWS is de-risked, the street will quickly start modelling these optionalities.

Vykat XR (Soleno) – First-to-market competitor

Vykat XR (diazoxide choline extended-release) is the cornerstone of Soleno’s story. The drug modulates ATP-sensitive potassium channels, impacting insulin secretion and hypothalamic signalling in ways that reduce hyperphagia and stabilize weight in PWS. The pivotal C602 study and its extension showed sizeable improvements in HQ-CT and other behavioral measures, leading to FDA approval in late March 2025 as the first therapy specifically indicated for hyperphagia in PWS in patients aged 4 years and older.

However, diazoxide-based therapy comes with a known safety and tolerability profile: hyperglycemia, fluid retention, edema and other metabolic effects that must be monitored closely. In the pivotal program, adverse events like hyperglycemia and edema were not rare and are clearly called out in the label and prescribing information. Real-world data from the first year of launch will be crucial in determining how aggressive physicians are in using Vykat XR in milder PWS or in patients with significant cardiometabolic comorbidities.

That is where ARD-101 has room to differentiate: if Phase 3 replicates the Phase 2 efficacy signal but maintains a cleaner metabolic safety profile, especially in combination with GLP-1s and other cardiometabolic drugs, many families and clinicians will at least want the option of an oral TAS2R agonist that is largely gut-restricted.

Side-by-side Snapshot – Aardvark vs Soleno

Financial Position and Ownership

Aardvark – Funding history and runway

Since inception in 2017, Aardvark has raised approximately $129M in equity financing prior to its IPO, supported by Decheng Capital, Vickers Venture Partners, Cormorant, Surveyor and other specialist life-science investors. The most recent private round was an $85M Series C in May 2024, explicitly framed as funding to push ARD-101 through Phase 3 in PWS and to advance ARD-201 in obesity.

In early 2025, Aardvark filed its S-1 to list on Nasdaq under the ticker AARD and subsequently completed its IPO, raising roughly $94M in gross proceeds according to local San Diego business coverage referencing the S-1. Combined, that puts the company’s lifetime capital raised well north of $200M before accounting for operating losses through late 2024.

The S-1 details net losses of $13.6M and $7.2M for 2022 and 2023, and preliminary losses of around $11.8M for the first nine months of 2024, with an accumulated deficit under $50M at that time. Assuming a Phase 3-style cash burn in the mid-tens of millions per year, the combination of pre-IPO cash and IPO proceeds provides a reasonably comfortable runway to complete the HERO trial and prepare an NDA, though management explicitly signals in the risk factors that additional capital will be required over time for commercialization and pipeline expansion.

Ownership and alignment

Post-IPO coverage based on the S-1 notes that CEO Tien-Li Lee is the largest single shareholder, with roughly 19% of the company, followed by Decheng and Vickers each around the high teens. The Foundation for Prader–Willi Research and other specialist funds are also on the cap table. This combination – significant founder/CEO ownership plus a syndicate of focused life-science investors and a patient-advocacy group – is exactly what you want to see in a small rare-disease biotech: incentives are tightly tied to long-term value creation in PWS and related indications.

Soleno – Cash, launch and institutional base

Soleno, by contrast, is a commercial-stage rare-disease company. Public filings and coverage around the Vykat XR approval and financing rounds show net losses scaling into the hundreds of millions as the company built out its PWS program, along with a significant cash balance (~$300M range across 2024/2025 reporting) and access to additional capital through equity and structured financings. The shareholder base is heavily institutional, with specialist healthcare funds and generalist growth investors anchoring positions around the FDA approval.

Analyst coverage frames Vykat XR as a potential blockbuster within the PWS niche, with some houses modelling peak sales north of $1B if adoption is strong and international expansion succeeds. That optimism is reflected in Soleno’s market cap. It also sets up the core relative-value question: how much optionality is the market giving to Aardvark at a fraction of Soleno’s valuation, and how does that evolve as HERO progresses?

Management Quality – AARD vs SLNO

On the Aardvark side, Dr. Lee’s profile is that of a repeat biotech innovator who has moved between strategy and hands-on innovation roles, and who retains a major ownership stake. The broader team – including a CMO with a successful exit to Vertex and an operations lead with deep Phase 3 execution experience – looks built for exactly what the company is doing now: running pivotal trials and getting ready for potential launch and combinations in obesity.

On the Soleno side, CEO Dr. Anish Bhatnagar brings almost three decades of biopharma and medical-device experience, including prior CEO roles and involvement in multiple approved products across different indications. His leadership has been publicly recognized (including a TIME100 Health recognition) for the impact of Vykat XR on families dealing with PWS. The Board and leadership team combine rare-disease commercialization, regulatory and financial experience, which is essential to maximize the value of a first-in-class approval.

From the perspective of a trader looking for pre-catalyst convexity, the key point is that neither company has an obvious “weak management” red flag: the edge, if any, is in where they are in the lifecycle. Soleno is in the messy reality of launch execution; Aardvark is still in the high-leverage catalyst phase, where a single dataset can flip the narrative.

Retail Sentiment and Flow – Reddit, Stocktwits, X

Retail Sentiment – Non-professional trader chatter only

A quick scan of discussions on Stocktwits, Reddit and X around AARD shows the classic early-stage pattern for a newly listed rare-disease biotech: relatively low message volume, but a high fraction of posts from biotech-focused accounts who explicitly compare Aardvark’s set-up with Soleno and with obesity names playing in the GLP-1 ecosystem. The tone is generally constructive: ARD-101 is seen as a “smart” gut-brain approach with room to coexist with GLP-1s rather than compete head-to-head.

On the Soleno side, sentiment is more polarized. Supporters lean heavily on the rarity of PWS, the depth of unmet need and the value of first-to-market status, with a narrative around “decade-long moat” if execution is strong. Skeptics worry about valuation relative to launch risk, metabolic side effects limiting uptake in milder patients, and the risk that a differentiated competitor like ARD-101 – or future gene therapies – may compress the long-term monopoly assumptions embedded in some bull cases.

As always, these are comments from non-professional traders and retail investors. They can be useful as a real-time snapshot of what the trading crowd is watching (e.g., trial timelines, cash runway, short interest), but they are not due-diligence and should never be used as a primary information source.

Catalyst Map 2025–2027

The core of the trade is simple: does ARD-101 clear HERO and set up a clean NDA? Around that central question, there are multiple secondary catalysts and data points.

AARD – Upcoming and potential catalysts

Soleno – Vykat XR execution catalysts

For Soleno, the catalyst map is different: instead of one binary readout, the story is a sequence of operational checkpoints:

– Quarterly revenue and script growth for Vykat XR in the U.S., including persistence, discontinuation rates and real-world safety signals.
– Progress on EU and other ex-U.S. regulatory filings and reimbursement negotiations.
– Potential label expansions or updated guidance in light of real-world data.
– Competitive moves from other PWS players (including Aardvark) and from broader obesity players whose therapies might overlap in this population.

For a pure RunUP strategy, Soleno is less attractive: most of the “binary” risk has already played out with the March 2025 approval. For Aardvark, we are squarely in the pre-event phase.

Risk, Red Flags and Scenarios

Key risks for Aardvark

1. Phase 3 risk: no matter how good the Phase 2 signal, pivotal studies can fail or come in mixed. A marginal HQ-CT improvement, a safety imbalance, or operational issues (e.g., high dropout, protocol deviations) could all derail the NDA plan and compress the valuation sharply. This is classic, unavoidable biotech risk.

2. Financing and dilution: even with sufficient cash for HERO and NDA-level activities, Aardvark will need more capital to commercialize ARD-101, expand into HO/obesity, or build a meaningful sales infrastructure. The timing of any future raise relative to HERO readout will matter a lot for existing shareholders.

3. Competitive landscape: Vykat XR has first-mover advantage and real-world data building up. If Soleno executes flawlessly and ARD-101’s advantage is modest, payers might push hard on step-therapy sequences that leave Aardvark with a narrower slice of the market. In parallel, gene-therapy and other approaches in PWS are moving forward and could change the medium-term game.

Key risks for Soleno

1. Launch execution: rare-disease launches are unforgiving. If uptake is slower than expected or if real-world tolerability issues emerge in milder PWS or in comorbid patients, revenue trajectories could undershoot bullish sell-side models that assume a smooth ramp to peak.

2. Competitive erosion: any positive HERO readout that shows comparable efficacy with a cleaner metabolic profile will immediately raise questions about long-term share and pricing power for Vykat XR, especially if ARD-101 fits better alongside GLP-1s or obesity regimens.

Scenario sketch for AARD (purely illustrative)

– Bull case: HERO delivers a clearly positive dataset with robust HQ-CT improvement and a clean safety profile. KOLs and PWS foundations embrace ARD-101 as a highly attractive option, either as first-line in certain phenotypes or as a key alternative when Vykat XR is not tolerated. The market starts to price Aardvark as a future commercial PWS franchise with pipeline upside; market cap migrates towards the low single-digit billions, closer to Soleno’s range.
– Base case: HERO is positive but not a slam dunk: efficacy is there but differences vs standard of care are nuanced, or safety/tolerability has some trade-offs. Aardvark still gets to an NDA, perhaps with some label complexity, and investor focus shifts to execution and positioning. Valuation re-rates, but less dramatically; the stock settles into a “show me” phase around launch.
– Bear case: HERO misses primary endpoints, has inconsistent results, or reveals a safety issue that undermines the PWS thesis. The stock re-prices closer to cash, the company has to reassess strategy around HO/obesity, and any future financings become much more dilutive.

Bottom Line – Why AARD vs SLNO Matters for a RunUP View

Aardvark vs Soleno in PWS is a clean illustration of the typical RunUP choice: do you want to be in the proven, already-approved name that now trades on execution and launch quality, or do you want convex exposure to the next catalyst event in the same niche? Soleno has already crossed the binary bridge with Vykat XR and now lives in the world of quarterly numbers and payer dynamics. Aardvark still has its main binary ahead of it – HERO Phase 3 – with a mechanism that, if confirmed, could deliver a differentiated safety and combination profile in a small but high-value orphan market.

The valuation gap between the two reflects that difference in stage and risk. If ARD-101 were a me-too copy of Vykat XR, there would be little reason to look at AARD. But the biology is distinct, the Phase 2 signal is encouraging, the management and investor base are credible, and the asset fits naturally into the broader obesity/GLP-1 combination wave. That doesn’t make the trade safe – Phase 3 is still binary – but it makes the asymmetry undeniable: Soleno is already priced as “winner that must execute”, Aardvark is still priced as “maybe”.

For now, the only honest conclusion is this: Aardvark is a high-risk, high-reward PWS bet with a properly funded, FDA-aligned pivotal program and a credible team, trading at a fraction of the value already assigned to the first-to-market player. Nothing here is a recommendation or a forecast; it is simply a structured view of where AARD sits on the risk/reward map relative to Soleno as we head towards the HERO readout in 2026.